SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 254 filers reported holding SAGE THERAPEUTICS INC in Q4 2018. The put-call ratio across all filers is 0.67 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2020 | $324,000 | -41.3% | 7,800 | +2.0% | 0.03% | -63.4% |
| Q4 2019 | $552,000 | -62.5% | 7,650 | -27.1% | 0.08% | -67.7% |
| Q3 2019 | $1,473,000 | -67.0% | 10,500 | -57.0% | 0.25% | -52.4% |
| Q2 2019 | $4,467,000 | -11.1% | 24,400 | -22.8% | 0.53% | -11.7% |
| Q1 2019 | $5,026,000 | +41.4% | 31,600 | -14.8% | 0.60% | +25.3% |
| Q4 2018 | $3,554,000 | -32.2% | 37,100 | 0.0% | 0.48% | -13.1% |
| Q3 2018 | $5,240,000 | -9.8% | 37,100 | 0.0% | 0.56% | -14.3% |
| Q2 2018 | $5,807,000 | +10.6% | 37,100 | +13.8% | 0.65% | +12.7% |
| Q1 2018 | $5,251,000 | +85.4% | 32,600 | +89.5% | 0.58% | +62.7% |
| Q4 2017 | $2,833,000 | +191.5% | 17,200 | +41.0% | 0.35% | +234.0% |
| Q2 2017 | $972,000 | +12.1% | 12,199 | 0.0% | 0.11% | +5.0% |
| Q1 2017 | $867,000 | -39.2% | 12,199 | -56.3% | 0.10% | -36.1% |
| Q4 2016 | $1,425,000 | -9.5% | 27,899 | -46.6% | 0.16% | -3.1% |
| Q2 2016 | $1,574,000 | -88.3% | 52,250 | -87.6% | 0.16% | -75.0% |
| Q1 2016 | $13,500,000 | – | 421,084 | – | 0.65% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DAFNA Capital Management LLC | 99,306 | $14,027,000 | 5.76% |
| Casdin Capital, LLC | 312,000 | $44,070,000 | 5.36% |
| Palo Alto Investors LP | 840,372 | $118,703,000 | 4.80% |
| BB BIOTECH AG | 1,071,373 | $151,331,000 | 4.00% |
| TRV GP II, LLC | 37,362 | $5,277,000 | 3.10% |
| Eversept Partners, LP | 43,621 | $6,161,466 | 2.70% |
| RA Capital Management | 350,933 | $49,569,000 | 2.65% |
| Eventide Asset Management | 494,000 | $69,778,000 | 2.56% |
| OAK RIDGE INVESTMENTS LLC | 241,099 | $34,055,000 | 1.88% |
| SUFFOLK CAPITAL MANAGEMENT LLC | 93,000 | $13,136,000 | 1.87% |